https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate...
/PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases,...
https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html
Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in...
/PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced positive top-line results from its randomized, double-blind, placebo-controlled, single dose...
https://www.news-medical.net/news/2008/09/01/41064.aspx
Bryostatin extends stroke treatment time to 24 hours, repairs brain tissue
Jun 19, 2019 - Scientists at the Blanchette Rockefeller Neurosciences Institute (BRNI) have discovered that Bryostatin -- and a related class of drugs discovered at BRNI --...
stroke treatmenttime to24 hoursbryostatinextends